RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company plans to share data from the initial dose levels later in the year. Preclinical studies have shown strong tumor targeting with minimal side effects, indicating potential for effective treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
- Half Year Report and Appendix 4D 31 December 2025
- Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
Later from Radiopharm Theranostics
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- RAD Completes Enrollment in Phase 2b Trial of RAD 101
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics